Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 4Myeloid 3Thoracic 1Plasma cell 1Lymphoid 1Genitourinary 1Gastrointestinal 1Classical hematology 1Breast 1

Conditions

Lung Neoplasms 5Carcinoma, Non-Small-Cell Lung 5Small Cell Lung Carcinoma 2Uterine Cervical Neoplasms 1Thrombocytopenia 1Primary Myelofibrosis 1Pathologic Complete Response 1Ovarian Neoplasms 1Myelodysplastic Syndromes 1Leukemia, Myeloid, Acute 1Hematologic Neoplasms 1Fallopian Tube Neoplasms 1Endometrial Neoplasms 1Breast Neoplasms 1Adenocarcinoma of Lung 1

Interventions

Nivolumab 3trametinib 2pertuzumab 2dabrafenib 2binimetinib 2Trastuzumab 2Azacitidine 2ulixertinib 1trastuzumab biosimilar HLX02 1tazemetostat 1sapanisertib 1romidepsin 1ribociclib 1relatlimab 1palbociclib 1osimertinib 1omipalisib 1margetuximab 1larotrectinib 1itacitinib 1ipatasertib 1erdafitinib 1defactinib 1copanlisib 1cobimetinib 1cc-486 1capivasertib 1bintrafusp alfa protein, human 1adavosertib 1X-Rays 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Hematologic Neoplasms × Tretinoin × Thoracic × Clear all
NCT02712905 2025-11-04

An Open-Label, Dose-Escalation/Dose-Expansion Safety Study of INCB059872 in Subjects With Advanced Malignancies

Incyte Corporation

Phase 1/2 Terminated
116 enrolled 36 charts
MyeloidOther hematologic neoplasmThoracic

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Hematologic Neoplasms, Primary Myelofibrosis, Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡